February 2018 – Content
Life Sciences
Agilent buys in biosensor and bioassay capabilities
Maravai adds nucleic acid synthesis reagent expert
PBI seeks fortune with purchase of biologics formulation firm
Bio-Techne buys cell culture reagent firm
Roche buys healthcare lab data specialist
Software firm acquires forensics laboratory
Nanosurf to develop live-cell weighing instrument
Japanese-French IVD joint venture dissolved
ONT key for most complete human DNA sequence
Cytosurge signs AFM instrument partners
Optibrium moves into new HQs following expansion
Illumina to sell TFS’ AmpliSeq technology to its customers
General Laboratory
General Electric CEO Flannery considers business break up
Horiba Scientific buys SPM product business
Elemental Scientific adds laser ablation capabilities
Nanoscribe celebrates 10th anniversary
Excelitas being sold to next equity investment owner
SDI expands with thermal control company
JEOL and Nikon open CLEM solution centre
TeakOrigin wins industry giant as partner
Process & hand-held instrumentation
Puridify becomes part of GE Healthcare
EPTEK’s CEM assets find interest with industry giant
Ametek launches process MS
Features
TDA 2018 Outlook: Analytical Instrument Industry
Japanese instrument exports continue to sink
Financials
Illumina ups guidance as NovaSeq exceeds expectations
Bio-Rad ahead of targets despite North American slowness
PSS ends tough year with strong growth forecast
PBI struggles to stay afloat with dwindling resources
Acquisitions boost sales of Takara’s reagents and instruments
AddLife growth benefits from acquisition
PacBio stock dips after sales miss
Weak Pound Sterling continues to drive growth for Halma
Agilent’s strength surprises both itself and analysts
Busch takeover causes management purge at Pfeiffer
Instrument sales begin to pick up for Horiba
Shimadzu raises guidance as markets strengthen
Solid results as Corning doubles down on pharma packaging
JEOL disappoints although prospects brighten
Instrument sales drive growth for IDEX
AHL returns to profit despite plunging sales
Order timing problems remain a headwind for L3
Danaher E&AS boosted by acquisitions and currency
Roper raises guidance after beating on earnings
Appointments